Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDA ...

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia [Accessibility Statement] Skip NavigationFDA PDUFA Goal Date Set for October 17, 2026PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- [Viatris Inc.](Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) fo ...

Core Insights - Recursion has reached a pivotal moment, transitioning from demonstrating AI's role in drug discovery to showcasing an AI-native operating system that can generate clinical proof and sustainable value [3] - The company enters 2026 with five clinical programs advancing and over $500 million in milestone payments earned to date, reflecting a robust pipeline and disciplined execution strategy [3][6] Business Highlights - Recursion's pipeline is diversified, powered by its AI-native Recursion OS, with both wholly-owned and partnered programs [4] - The company achieved its first clinical validation of the Recursion OS in Familial Adenomatous Polyposis (FAP), with 75% of evaluable patients showing reductions in total polyp burden [6][9] - Recursion has received $134 million in milestone payments from its collaboration with Sanofi, with five discovery program packages accepted to date [6][14] Financial Performance - Total revenue for Q4 2025 was $35.5 million, a significant increase from $4.5 million in Q4 2024, driven by milestone payments and collaboration agreements [15] - Research and development expenses for Q4 2025 were $95.9 million, slightly lower than $98.3 million in Q4 2024, while total R&D expenses for the year were $475.3 million compared to $314.4 million in 2024 [15][22] - The net loss for Q4 2025 was $108.1 million, an improvement from a net loss of $178.9 million in Q4 2024, with a total net loss of $644.8 million for the year [15][22] Pipeline and Milestones - Recursion's pipeline includes several promising candidates, such as REC-4881 for FAP, REC-617 for advanced solid tumors, and REC-7735 for PI3Kα H1047R mutation [7][9] - Upcoming milestones include FDA engagement for REC-4881 and additional Phase 1/2 clinical data expected in 2026 [9][12] - The company anticipates further advancements in its partnered discovery programs, with potential for additional near-term milestones as programs progress [8][14] Cash Position - As of December 31, 2025, Recursion had cash and cash equivalents of $754 million, providing a runway into early 2028 without additional financing [6][15] - The company achieved a cash operating expense of approximately $399.2 million for 2025, reflecting improved operational efficiency [12][22]

Core Viewpoint - Novo Nordisk, once a leader in the GLP-1 weight loss drug market, is facing significant challenges, including pricing pressure, competition, and setbacks in its drug pipeline, leading to a substantial decline in stock value [1][10][14]. Market Position and Competition - Novo Nordisk's market share has decreased to approximately 40%, while Eli Lilly has captured about 60% of the market [2]. - The company is aware of the competitive landscape and pricing challenges, with CEO Mike Doustdar indicating that sales are expected to decline before recovering [2][11]. Financial Performance - The combined sales of Novo's two major drugs, Ozempic and Wegovy, reached around $32 billion, constituting about 67% of total sales last year [6]. - In contrast, Eli Lilly's top two drugs generated approximately $37 billion, representing 56% of its total sales [6]. - Novo Nordisk anticipates a sales and profit decline of 5% to 13% in 2026, marking the first annual sales drop since 2017 [16]. Stock Performance - Novo's stock has plummeted by 75% from its peak of over 1,000 Danish kroner per share in mid-2024, while Eli Lilly's stock has surged by 400% during the same period [13][14]. Future Prospects - The company is pinning hopes on new products like the Wegovy pill and CagriSema to drive future growth, although recent trial results for CagriSema have raised doubts about its commercial viability [17][18]. - The competitive landscape is expected to intensify as other large-cap pharmaceutical companies plan to enter the weight loss drug market with differentiated offerings [17].

At close, Sensex was up a little over 50 points at 82,276. This marks a fall of around 682 points from its intraday high of 82,958, which it had hit in the morning amid strong buying in Today’s gains were led by metals, with the Nifty Metal index rising 2.7%. IT stocks, which had surged sharply in the morning, also pared partial gains by the end of the session. The Nifty IT index closed 1.57% higher, while the auto and pharma indices gained 1.85% each. FMCG, PSU Banks, realty, along with oil & gas indices, ...

Group 1 - GSK has entered into an agreement to acquire Canada's 35Pharma, aiming to enhance its portfolio in diseases associated with obesity [1]

Novo Nordisk A/S (NYSE:NVO) announced plans on Tuesday to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027.The price reduction will affect the obesity injection Wegovy, its pill counterpart, the diabetes shot Ozempic, and the oral diabetes drug Rybelsus. The new list price for these medications will be $675 per month, a significant drop from their current prices, which range from $1,027 to $1,350 per month.According to Millar, out-of-pocket costs for commercially insured pati ...

Skip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitivBMW to recall nearly 59,000 vehicles in US over damaged wiring harness, NHTSA saysFebruary 25, 20268:26 AM UTCUpdated 5 mins agoBy ReutersThe BMW logo is seen during the 2016 New York International Auto Show in Manhattan, New York, March 24, 2016. REUTERS/Eduardo Munoz/File Photo Purchase Licensing Rights, opens new tabCompaniesBayerische Motoren Werke AGFeb 25 (Reuters) - BMW (BMWG.DE), opens n ...

（同仁堂公告） 近日，同仁堂（600085）发布公告称，公司分支机构同仁堂制药厂收到加拿大卫生部核准签发的《产品 许可证（三类）》，儿感清口服液、锁阳固精丸、人参健脾丸、大黄虫丸获得加拿大产品注册。 公告同样指出，这些产品若在加拿大销售，还需完成包括生产场地的加拿大生产质量体系认证等行政审 批事项，该等审批可能存在一定不确定性。本次获批事宜对公司近期经营业绩不会产生重大影响。 ...

转自：福建省药品监督管理局网站 2026年2月14日 福建省药品监督管理局GMP符合性检查结果公告（2026年第6号） 根据《药品管理法》、《药品生产监督管理办法》有关规定，经现场检查并综合评定，现将厦门伯马药业有限公司《药品生产质量管理规范》 符合性检查结果公告。 | 企业名称 | 检查地址 | 检查范围 | 检查时间 | 检 类 查 | | --- | --- | --- | --- | --- | | | | | | 型 结 | | | | | | 果 | | | 1. 持有人检查地址：厦门市 | 1.检查范围：盐酸莫西沙星氯化钠注射液（250ml：盐酸莫 | 1.持有人检查时 | 符 | | | 海沧区海沧大道567号厦门中 | 西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g，批准文 | 间：2025年12月25 | | | 厦门伯马药业有限公司 | 心E座913单元 | 号：国药准字H20243011） | 日-12月26日 | 依 | | （受托方：广东大翔制 | | | | 申 | | 药有限公司） | 2.延伸检查地址：广州市增 | 2.生产类型：委托生产 | 2.延伸检查时间： ...